![](https://testing.innoplexus.com/wp-content/plugins/relevant/images/no_preview.jpg)
Ontosight® – Biweekly NewsletterJune 17th – June 30th, 2024 –Read More
Ontosight® – Biweekly NewsletterJune 17th – June 30th, 2024 –Read More
May 24
Apr 24
Innoplexus wins Horizon Interactive Gold Award for Curia App
Read MoreAccording to one study, the United States healthcare system ranked last among 11 industrialized nations in terms of access, equity, quality, efficiency, and healthy lives. And it’s not as if there was foreign bias skewing the results — the Commonwealth Fund, which published the study, is a U.S.-based foundation aiming to improve the overall state of healthcare through objective analysis. Their analysis found that the United States spent $8,508 per person on healthcare in 2011, compared with $3,406 in the United Kingdom, which ranked first overall. Other findings suggest that hospitals could increase care output by as much as 26% if they were to find new ways to eliminate inefficiency in their operations. The blockchain may serve as the means to realize greater outputs, especially if hospitals are able to employ it in a comprehensive manner, from improving time-consuming electronic health records systems to rooting out fraud and exploring other ways that the technology can help strengthen the standing of the American healthcare system.
Drug counterfeiting takes a staggering toll on global health and the cost of pharmaceuticals. The World Health Organization estimates that worldwide, 10% of pharmaceutical drugs are counterfeit. This amounts to $75 billion annually going to illegal drug manufacturers, who are responsible for an estimated 100,000 deaths due to the drugs being either unsafe, ineffective, or both. However, this is a particularly difficult market to police, as 40% of pharmaceutical drugs are manufactured overseas, and approximately 80% of the active medicinal components of drugs are imported.
These figures illustrate why the blockchain is so needed as a record to unify drug suppliers, with the decentralized technology taking the place of what have proven to be dangerously centralized databases. The blockchain record would provide greater accountability of supply chain members and allow authorities to identify and root out fraudulent batches more rapidly. See the section on supply chain to understand how blockchains can improve provenance of goods like pharmaceuticals.
Risk aversion in medical testing and research has led to an industry standard of near 100% source data verification, which is a measure to ensure that no fraudulent data exists in any aspect of a study. This is costly, with studies finding that more than one-third of a Phase 3 trial budget is typically consumed by source data verification processes. In medical device clinical trials, 15% of the overall budget is typically dedicated to SDV monitoring processes, with little return on investment. The $150,000 spent on SDV in a million dollar trial has been found to produce a return on investment of $525.
By utilizing the blockchain’s cryptographic hashing systems, which verify and timestamp data, these costs could be drastically reduced. By hashing and storing each element of a clinical trial as the proceedings occur, the current post-study verification processes — which is riddled with costly redundancy — will become a tragic figment of the past.
You can read the full article here: disruptordaily.
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…